Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TACR1 | P25103 | 2/20 | 0.43 |
| ▸ | KLK5 | Q9Y337 | 1/20 | 0.43 |
| ▸ | SCN9A | Q15858 | 13/20 | 0.42 |
| ▸ | CTSS | P25774 | 3/20 | 0.41 |
| ▸ | CTSK | P43235 | 3/20 | 0.41 |
| ▸ | SCN10A | Q9Y5Y9 | 5/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 5/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30705546 | 0.82 | TACR1 (0.48) | TACR1KLK5SCN9ACTSSCTSK | |
| SCHEMBL14280758 | 0.82 | TACR1 (0.46) | TACR1KLK5SCN9ACTSSCTSK | |
| SCHEMBL29039962 | 0.78 | KLK5 (0.49) | TACR1KLK5SCN9ACTSSCTSK | |
| SCHEMBL16464699 | 0.76 | HDAC6 (0.60) | TACR1KLK5CTSSCTSK | |
| SCHEMBL16464697 | 0.76 | HDAC6 (0.60) | TACR1KLK5CTSSCTSK | |
| SCHEMBL24309187 | 0.76 | TACR1 (0.55) | TACR1KLK5SCN9ACTSSCTSK | |
| SCHEMBL7842742 | 0.76 | TACR1 (0.55) | TACR1KLK5SCN9ACTSSCTSK | |
| SCHEMBL29478098 | 0.76 | TACR1 (0.55) | TACR1KLK5SCN9ACTSSCTSK | |
| SCHEMBL2584054 | 0.76 | TACR1 (0.55) | TACR1KLK5SCN9ACTSSCTSK | |
| SCHEMBL14280757 | 0.76 | KLK5 (0.46) | TACR1KLK5SCN9ACTSSCTSK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090099176-A1 | PYRROLOPYRIDINE-2-CARBOXYLIC ACID AMIDES | PROSIDION LIMITED (GB) | 2009-04-16 | — | — | US | disclosed |
| US-20090099176-A1 | PYRROLOPYRIDINE-2-CARBOXYLIC ACID AMIDES | PROSIDION LIMITED (GB) | 2009-04-16 | — | — | US | disclosed |
| EP-1819332-B1 | PYRROLOPYRIDINE-2-CARBOXYLIC ACID AMIDES | PROSIDION LTD (GB) | 2009-03-11 | — | — | EP | disclosed |
| EP-1819332-A2 | PYRROLOPYRIDINE-2-CARBOXYLIC ACID AMIDES | Prosidion Limited (GB) | 2007-08-22 | — | — | EP | disclosed |
| WO-2006059164-A2 | PYRROLOPYRIDINE-2-CARBOXYLIC ACID AMIDES | PROSIDION LIMITED (GB) | 2006-06-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090099176-A1 | PYRROLOPYRIDINE-2-CARBOXYLIC ACID AMIDES | PC, GOT2, PDK1 | TACR1 1770/4885KLK5 3112/4885SCN9A 2395/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.